Certara (NASDAQ:CERT) vs. Health In Tech (NASDAQ:HIT) Head-To-Head Survey

Health In Tech (NASDAQ:HIT) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Profitability

This table compares Health In Tech and Certara’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health In Tech	N/A	N/A	N/A
Certara	-16.75%	3.86%	2.65%

Volatility and Risk

Health In Tech has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Comparatively, Certara has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Institutional and Insider Ownership

74.0% of Certara shares are owned by institutional investors. 77.7% of Health In Tech shares are owned by insiders. Comparatively, 1.1% of Certara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Health In Tech and Certara”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health In Tech	$34.08 million	2.15	-$1.31 million	($0.02)	-56.00
Certara	$418.84 million	2.94	-$1.60 million	($0.45)	-17.93

Health In Tech has higher earnings, but lower revenue than Certara. Health In Tech is trading at a lower price-to-earnings ratio than Certara, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Health In Tech and Certara, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health In Tech	1	0	0	1	2.50
Certara	1	6	4	1	2.42

Health In Tech currently has a consensus target price of $4.00, indicating a potential upside of 257.14%. Certara has a consensus target price of $8.28, indicating a potential upside of 2.57%. Given Health In Tech’s stronger consensus rating and higher probable upside, research analysts clearly believe Health In Tech is more favorable than Certara.

About Health In Tech

Health in Tech, Inc. engages in the provision of insurance technology platforms which offer a marketplace of processes in the healthcare industry. Its services include Stone Mountain Risk, eDIYBS, HI Card, HI Performance Network, and Ancillary Products. The company was founded by Tim Johnson in 2014 and is headquartered in Stuart, FL.

About Certara

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.